In a post‑menopausal woman or man over 65 with anterior vertebral wedging ≥20 % (consistent with a fracture) after excluding trauma, metastasis, infection, or metabolic bone disease, should bisphosphonate therapy be initiated?

Bisphosphonate Therapy for Vertebral Wedging Fractures

Yes, bisphosphonate therapy should be initiated in postmenopausal women or men over 65 with anterior vertebral wedging ≥20% consistent with a fragility fracture, as this represents established osteoporosis with a prevalent vertebral fracture—a strong indication for pharmacologic treatment to prevent subsequent fractures. 1

Why Treatment is Indicated

A vertebral fracture is not just a radiographic finding—it is a clinical sentinel event that dramatically increases future fracture risk. The presence of a vertebral fracture, even if asymptomatic, places patients at high risk for subsequent vertebral, hip, and non-vertebral fractures. 1, 2

• Vertebral fractures predict future fracture risk at all skeletal sites, including hip fractures, which carry significant morbidity and mortality. 3, 2
• Patients with one vertebral fracture have approximately 5-fold increased risk of another vertebral fracture and 2-3 fold increased risk of hip fracture. 1
• The goal of treatment is fracture prevention, which directly impacts mortality, morbidity, and quality of life. 1

First-Line Treatment: Oral Bisphosphonates

Alendronate or risedronate should be prescribed as first-line therapy because these agents have demonstrated efficacy in reducing vertebral, non-vertebral, and hip fractures in patients with prevalent vertebral fractures. 1, 2

• Bisphosphonates reduce vertebral fracture risk by approximately 40-50% over 3 years in patients with prevalent vertebral fractures. 2
• Alendronate and risedronate are preferred due to established efficacy, favorable safety profile, low cost (generic availability), and extensive clinical experience. 1
• The number needed to treat (NNT) ranges from 15-64 for alendronate and 8-26 for risedronate to prevent one vertebral fracture. 2

Alternative Agents When Oral Bisphosphonates Cannot Be Used

If oral bisphosphonates are not tolerated or contraindicated (esophageal abnormalities, inability to remain upright for 30 minutes, malabsorption), the treatment hierarchy is: 1, 4

1. Intravenous bisphosphonates (zoledronic acid annually or ibandronate every 3 months) for patients with oral intolerance, dementia, malabsorption, or non-compliance. 1
2. Denosumab (subcutaneous every 6 months) as a second-line agent. 1, 4
3. Teriparatide (anabolic agent) for patients with very severe osteoporosis or multiple vertebral fractures. 1

Mandatory Pre-Treatment Steps

Before initiating bisphosphonates, vitamin D deficiency must be corrected to prevent hypocalcemia and optimize treatment efficacy. 4

• Check baseline 25(OH)D level; target ≥32 ng/mL before starting bisphosphonates. 4
• For 25(OH)D >15 ng/mL: prescribe vitamin D3 2,000 IU daily for 12 weeks, then 1,000-2,000 IU daily for maintenance. 4
• For 25(OH)D <15 ng/mL: prescribe vitamin D2 50,000 IU weekly for 8-12 weeks, then monthly. 4
• Hypocalcemia risk is highest with IV bisphosphonates (zoledronic acid) due to rapid bone uptake and acute suppression of bone turnover. 4

Check serum creatinine before initiating therapy—bisphosphonates are contraindicated if creatinine clearance <30 mL/min. 4, 5

Concurrent Supplementation During Treatment

All patients receiving bisphosphonates require: 1, 4

• Calcium 1,000-1,200 mg daily (total intake from diet plus supplements). 1, 4
• Vitamin D 800-1,000 IU daily for maintenance after repletion. 1, 4
• These supplements were part of all major bisphosphonate trials demonstrating fracture reduction. 1

Treatment Duration and Monitoring

Bisphosphonates should be prescribed for 3-5 years initially, with reassessment at that point to determine need for continuation or drug holiday. 1

• Patients who remain at high risk (multiple fractures, very low BMD, ongoing glucocorticoid use) should continue treatment beyond 5 years. 1
• Do not perform routine BMD monitoring during the initial 5-year treatment period—instead, assess annually for adherence, side effects, and new fractures. 6
• After 5 years, consider drug holiday in lower-risk patients, but continue treatment in those with persistent high fracture risk. 6

Critical Safety Considerations

Oral bisphosphonates must be taken correctly to prevent esophageal complications: 1

• Take with full glass of water on empty stomach
• Remain upright for at least 30 minutes
• Do not eat or drink anything for 30 minutes after administration

Rare but serious adverse effects include: 1

• Osteonecrosis of the jaw (incidence <1 per 100,000 person-years)—highest risk with recent dental surgery. Complete necessary dental work before starting bisphosphonates. 1, 4
• Atypical femoral fractures—risk increases with treatment duration beyond 5 years. 4, 6
• Acute phase reaction with IV bisphosphonates (fever, myalgias)—typically occurs only with first infusion. 1

Common Pitfalls to Avoid

• Do not delay treatment while waiting for additional testing or specialist referral—vertebral fractures are sufficient indication for immediate treatment. 1
• Do not start bisphosphonates without correcting vitamin D deficiency first, especially before IV formulations. 4
• Do not prescribe bisphosphonates in patients with CrCl <30 mL/min—use alternative agents like denosumab. 4, 5
• Do not forget calcium and vitamin D supplementation—bisphosphonates alone are insufficient. 1, 4
• Do not assume the fracture is "just degenerative"—anterior wedging ≥20% after excluding trauma, malignancy, and infection represents an osteoporotic fracture requiring treatment. 1